{
    "filename": "pdf.pdf",
    "content_type": "application/pdf",
    "file_size": 158235,
    "metadata": {
        "identifiers": {
            "doi": "10.1016/s0140-6736(20)30304-4",
            "arxiv": null,
            "isbn": null,
            "doc_id": null,
            "url": "http://www.thelancet.com/article/S0140673620303044/pdf"
        },
        "title": "Baricitinib as potential treatment for 2019-nCoV acute respiratory disease",
        "author": "Peter Richardson, Ivan Griffin, Catherine Tucker, Dan Smith, Olly Oechsle, Anne Phelan, Justin Stebbing",
        "date": 2020,
        "journal": "The Lancet",
        "volume": "395",
        "abstract": "Given the scale and rapid spread of the 2019 novel coronavirus (2019-nCoV) acute respiratory disease, there is an immediate need for medicines that can help before a vaccine can be produced. Results of rapid sequencing of 2019-nCoV, coupled with molecular modelling based on the genomes of related virus proteins,[<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>] have suggested a few compounds that are likely to be effective, including the anti-HIV lopinavir plus ritonavir combination.",
        "references": "@misc{gruber-a,\n  author = {Gruber, C.C. and Steinkellner, G.},\n  title = {Wuhan coronavirus 2019-nCoV\u2014what we can find out on a structural bioinformatics level},\n  date = \"Jan\" # \"Feb\",\n  volume = {23},\n  url = {https://innophore.com/2019-ncov/},\n  pages = {2020},\n  unmatched-volume = {3,},\n  number = {2020},\n  language = {}\n}\n@article{segler2018a,\n  author = {Segler, M.H.S. and Preuss, M. and Waller, P.},\n  title = {Planning chemical syntheses with deep neural networks and symbolic AI},\n  journal = {Nature},\n  date = {2018},\n  volume = {555},\n  pages = {604\u201310},\n  language = {}\n}\n@misc{zhao-a,\n  author = {Zhao, Y. and Zhao, Z. and Wang, Y.},\n  title = {Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. BioRxiv 2020; published online Jan 26},\n  doi = {DOI:https://doi.19985},\n  more-authors = {true},\n  language = {}\n}\n@incollection{lu-a,\n  author = {Lu, R. and Zhao, X. and Li, J.},\n  title = {Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding},\n  source = {Lancet 2020; published online},\n  date = {Jan},\n  volume = {30},\n  url = {https://doi.org/10.1016/S0140-6736},\n  more-authors = {true},\n  language = {}\n}\n@article{pu2018a,\n  author = {Pu, S.Y. and Xiao, F. and Schor, S.},\n  title = {Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment},\n  journal = {Antiviral Res},\n  date = {2018},\n  volume = {155},\n  pages = {67\u201375},\n  more-authors = {true},\n  language = {}\n}\n@article{sorrell2016a,\n  author = {Sorrell, F. and Szklarz, M. and Abdul Areez, K.R.},\n  title = {Family-wide structural analysis of human numb-associated protein kinases},\n  journal = {Structure},\n  date = {2016},\n  volume = {24},\n  pages = {401\u201311},\n  more-authors = {true},\n  language = {}\n}\n@incollection{chen-a,\n  author = {Chen, N. and Zhou, M. and Dong, X.},\n  title = {Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study},\n  source = {Lancet 2020; published online},\n  date = {Jan},\n  volume = {29},\n  url = {https://doi.org/10.1016/S0140-6736},\n  more-authors = {true},\n  language = {}\n}\n",
        "links": [
            "https://doi.org/10.1016/"
        ],
        "emails": [
            "j.stebbing@imperial.ac.uk"
        ],
        "pages": "e30-e31",
        "cited_by": 4,
        "references_ris": "TY  - GEN\nAU  - Gruber, C.C.\nAU  - Steinkellner, G.\nTI  - Wuhan coronavirus 2019-nCoV\u2014what we can find out on a structural bioinformatics level\nPY  - \"Jan\" # \"Feb\"\nDA  - \"Jan\" # \"Feb\"\nVL  - 23\nUR  - https://innophore.com/2019-ncov/\nSP  - 2020\nC1  - 3,\nIS  - 2020\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Segler, M.H.S.\nAU  - Preuss, M.\nAU  - Waller, P.\nTI  - Planning chemical syntheses with deep neural networks and symbolic AI\nT2  - Nature\nPY  - 2018\nDA  - 2018\nVL  - 555\nSP  - 604\nEP  - 10\nLA  - \nER  - \n\nTY  - GEN\nAU  - Zhao, Y.\nAU  - Zhao, Z.\nAU  - Wang, Y.\nTI  - Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. BioRxiv 2020; published online Jan 26\nDO  - https://doi.19985\nC1  - true\nLA  - \nER  - \n\nTY  - CHAP\nAU  - Lu, R.\nAU  - Zhao, X.\nAU  - Li, J.\nTI  - Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding\nT2  - Lancet 2020; published online\nPY  - Jan\nDA  - Jan\nVL  - 30\nUR  - https://doi.org/10.1016/S0140-6736\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Pu, S.Y.\nAU  - Xiao, F.\nAU  - Schor, S.\nTI  - Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment\nT2  - Antiviral Res\nPY  - 2018\nDA  - 2018\nVL  - 155\nSP  - 67\nEP  - 75\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Sorrell, F.\nAU  - Szklarz, M.\nAU  - Abdul Areez, K.R.\nTI  - Family-wide structural analysis of human numb-associated protein kinases\nT2  - Structure\nPY  - 2016\nDA  - 2016\nVL  - 24\nSP  - 401\nEP  - 11\nC1  - true\nLA  - \nER  - \n\nTY  - CHAP\nAU  - Chen, N.\nAU  - Zhou, M.\nAU  - Dong, X.\nTI  - Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study\nT2  - Lancet 2020; published online\nPY  - Jan\nDA  - Jan\nVL  - 29\nUR  - https://doi.org/10.1016/S0140-6736\nC1  - true\nLA  - \nER  - \n\n",
        "author_conclusions": [],
        "table_captions": [],
        "figure_captions": []
    },
    "sections": {
        "introduction": [
            "Given the scale and rapid spread of the 2019 novel coronavirus (2019-nCoV) acute respiratory disease, there is an immediate need for medicines that can help before a vaccine can be produced. Results of rapid sequencing of 2019-nCoV, coupled with molecular modelling based on the genomes of related virus proteins,[<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>] have suggested a few compounds that are likely to be effective, including the anti-HIV lopinavir plus ritonavir combination.",
            "BenevolentAI\u2019s knowledge graph is a large repository of structured medical information, including numerous connections extracted from scientific literature by machine learning.[<a class=\"ref-link\" id=\"c2\" href=\"#r2\">2</a>] Together with customisations bespoke to 2019-nCoV, we used BenevolentAI to search for approved drugs that could help, focusing on those that might block the viral infection process. We identified baricitinib, which is predicted to reduce the ability of the virus to infect lung cells."
        ]
    },
    "structured_content": {
        "Baricitinib as potential treatment for": [
            "Given the scale and rapid spread of the 2019 novel coronavirus (2019-nCoV) acute respiratory disease, there is an immediate need for medicines that can help before a vaccine can be produced. Results of rapid sequencing of 2019-nCoV, coupled with molecular modelling based on the genomes of related virus proteins,[<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>] have suggested a few compounds that are likely to be effective, including the anti-HIV lopinavir plus ritonavir combination.",
            "BenevolentAI\u2019s knowledge graph is a large repository of structured medical information, including numerous connections extracted from scientific literature by machine learning.[<a class=\"ref-link\" id=\"c2\" href=\"#r2\">2</a>] Together with customisations bespoke to 2019-nCoV, we used BenevolentAI to search for approved drugs that could help, focusing on those that might block the viral infection process. We identified baricitinib, which is predicted to reduce the ability of the virus to infect lung cells.",
            "Most viruses enter cells through receptor-mediated endocytosis. The receptor that 2019-nCoV uses to infect lung cells might be ACE2, a cellsurface protein on cells in the kidney, blood vessels, heart, and, importantly, lung AT2 alveolar epithelial cells (figure). These AT2 cells are particularly prone to viral infection.[<a class=\"ref-link\" id=\"c3\" href=\"#r3\">3</a>] One of the known regulators of endocytosis is the AP2-associated protein kinase 1 (AAK1). Disruption of AAK1 might, in turn, interrupt the passage of the virus into cells and also the intracellular assembly of virus particles.[<a class=\"ref-link\" id=\"c4\" href=\"#r4\">4</a>]",
            "Of 378 AAK1 inhibitors in the knowledge graph, 47 have been approved for medical use and six inhibited AAK1 with high affinity. These included a number of oncology drugs such as sunitinib and erlotinib, both of which have been shown to inhibit viral infection of cells through"
        ],
        "Expressed in": [],
        "Involved in": [],
        "Viral entry": [],
        "Involved in Endocytosis": [],
        "Mediates GAK": [],
        "Involved in Cytokine signalling": [],
        "Inhibits Inhibits Inhibits Inhibits": [
            "Figure: The BenevolentAI knowledge graph The BenevolentAI knowledge graph integrates biomedical data from structured and unstructured sources. It is queried by a fleet of algorithms to identify new relationships to suggest new ways of tackling disease. 2019-nCoV=2019 novel coronavirus. AAK1=AP2-associated protein kinase 1. GAK=cyclin G-associated kinase. JAK1/2=janus kinase 1/2.",
            "the inhibition of AAK1.5 However, these compounds bring serious side-effects, and our data infer high doses to inhibit AAK1 effectively. We do not consider these drugs would be a safe therapy for a population of sick and infected people.",
            "By contrast, one of the six highaffinity AAK1-binding drugs was the janus kinase inhibitor baricitinib, which also binds the cyclin G-associated kinase, another regulator of endo\u00ad cytosis.[<a class=\"ref-link\" id=\"c6\" href=\"#r6\">6</a>] Because the plasma concen\u00ad tration of baricitinib on therapeutic dosing (either as 2 mg or 4 mg once daily) is sufficient to inhibit AAK1, we suggest it could be trialled, using an appropriate patient population with 2019-nCoV acute respiratory disease, to reduce both the viral entry and the inflammation in patients, using endpoints such as the MuLBSTA score, an early warning model for predicting mortality in viral pneumonia.[<a class=\"ref-link\" id=\"c7\" href=\"#r7\">7</a>]",
            "JS is editor-in-chief of Oncogene. JS has previously sat on a number of scientific advisory boards, including BenevolentAI, and has consulted with Lansdowne partners, Vitruvian, and Social Impact Capital; he now sits on the Board of Directors for BB Biotech Healthcare Trust and chairs Xerion Healthcare. All other authors are employees of BenevolentAI. Events in relation to the 2019-nCoV outbreak are evolving rapidly, and we make our initial thoughts available in this Correspondence in good faith and to assist in the global response. Our early investigations and suggestions require further detailed work and analysis and should not be relied on as constituting any kind of medical or other advice or recommendation.",
            "BenevolentAI, London, UK (PR, IG, CT, DS, OO, AP); and Department of Surgery and Cancer, Imperial College London, London SW7 2AZ, UK (JS)",
            "Submissions should be made via our electronic submission system at http://ees.elsevier.com/ thelancet/"
        ]
    },
    "participants": [],
    "statistics": [],
    "keywords": [
        "coronavirus",
        "baricitinib",
        "related virus",
        "acute respiratory disease",
        "hiv lopinavir",
        "associated protein kinase 1",
        "ACE2",
        "ritonavir combination",
        "immediate need",
        "rapid sequencing",
        "rapid spread",
        "lopinavir",
        "novel coronavirus",
        "molecular modelling"
    ],
    "keyword_relevance": {
        "associated protein kinase 1": 0.32432432432432434,
        "coronavirus": 0.13513513513513514,
        "novel coronavirus": 0.10810810810810811,
        "baricitinib": 0.08108108108108109,
        "acute respiratory disease": 0.08108108108108109,
        "ACE2": 0.08108108108108109,
        "related virus": 0.02702702702702703,
        "ritonavir combination": 0.02702702702702703,
        "immediate need": 0.02702702702702703,
        "rapid sequencing": 0.02702702702702703,
        "rapid spread": 0.02702702702702703,
        "lopinavir": 0.02702702702702703,
        "molecular modelling": 0.02702702702702703,
        "hiv lopinavir": 0.0
    },
    "species": [],
    "summary": [
        "Given the scale and rapid spread of the 2019 novel coronavirus (2019-nCoV) acute respiratory disease, there is an immediate need for medicines that can help before a vaccine can be produced.",
        "Results of rapid sequencing of 2019-nCoV, coupled with molecular modelling based on the genomes of related virus proteins,[<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>] have suggested a few compounds that are likely to be effective, including the anti-HIV lopinavir plus ritonavir combination.",
        "BenevolentAI\u2019s knowledge graph is a large repository of structured medical information, including numerous connections extracted from scientific literature by machine learning.[<a class=\"ref-link\" id=\"c2\" href=\"#r2\">2</a>] Together with customisations bespoke to 2019-nCoV, the authors used BenevolentAI to search for approved drugs that could help, focusing on those that might block the viral infection process.",
        "The authors identified baricitinib, which is predicted to reduce the ability of the virus to infect lung cells.",
        "Most viruses enter cells through receptor-mediated endocytosis.",
        "The receptor that 2019-nCoV uses to infect lung cells might be ACE2, a cellsurface protein on cells in the kidney, blood vessels, heart, and, importantly, lung AT2 alveolar epithelial cells.",
        "These AT2 cells are prone to viral infection.[<a class=\"ref-link\" id=\"c3\" href=\"#r3\">3</a>] One of the known regulators of endocytosis is the AP2-associated protein kinase 1 (AAK1).",
        "Of 378 AAK1 inhibitors in the knowledge graph, 47 have been approved for medical use and six inhibited AAK1 with high affinity.",
        "These included a number of oncology drugs such as sunitinib and erlotinib, both of which have been shown to inhibit viral infection of cells through",
        "AAK1=AP2-associated protein kinase 1.",
        "GAK=cyclin G-associated kinase.",
        "JAK1/2=janus kinase 1/2.",
        "The inhibition of AAK1.5 these compounds bring serious side-effects, and the data infer high doses to inhibit AAK1 effectively.",
        "One of the six highaffinity AAK1-binding drugs was the janus kinase inhibitor baricitinib, which binds the cyclin G-associated kinase, another regulator of endo\u00ad cytosis.[<a class=\"ref-link\" id=\"c6\" href=\"#r6\">6</a>] Because the plasma concen\u00ad tration of baricitinib on therapeutic dosing is sufficient to inhibit AAK1, the authors suggest it could be trialled, using an appropriate patient population with 2019-nCoV acute respiratory disease, to reduce both the viral entry and the inflammation in patients, using endpoints such as the MuLBSTA score, an early warning model for predicting mortality in viral pneumonia.[<a class=\"ref-link\" id=\"c7\" href=\"#r7\">7</a>]",
        "JS has previously sat on a number of scientific advisory boards, including BenevolentAI, and has consulted with Lansdowne partners, Vitruvian, and Social Impact Capital; he sits on the Board of Directors for BB Biotech Healthcare Trust and chairs Xerion Healthcare.",
        "BenevolentAI, London, UK (PR, IG, CT, DS, OO, AP); and Department of Surgery and Cancer, Imperial College London, London SW7 2AZ, UK (JS)"
    ],
    "structured_summary": {
        "Introduction": [
            "Given the scale and rapid spread of the 2019 novel coronavirus (2019-nCoV) acute respiratory disease, there is an immediate need for medicines that can help before a vaccine can be produced.",
            "Results of rapid sequencing of 2019-nCoV, coupled with molecular modelling based on the genomes of related virus proteins,[<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>] have suggested a few compounds that are likely to be effective, including the anti-HIV lopinavir plus ritonavir combination.",
            "BenevolentAI\u2019s knowledge graph is a large repository of structured medical information, including numerous connections extracted from scientific literature by machine learning.[<a class=\"ref-link\" id=\"c2\" href=\"#r2\">2</a>] Together with customisations bespoke to 2019-nCoV, the authors used BenevolentAI to search for approved drugs that could help, focusing on those that might block the viral infection process."
        ],
        "Results": [
            "The authors identified baricitinib, which is predicted to reduce the ability of the virus to infect lung cells.",
            "Most viruses enter cells through receptor-mediated endocytosis.",
            "The receptor that 2019-nCoV uses to infect lung cells might be ACE2, a cellsurface protein on cells in the kidney, blood vessels, heart, and, importantly, lung AT2 alveolar epithelial cells.",
            "These AT2 cells are prone to viral infection.[<a class=\"ref-link\" id=\"c3\" href=\"#r3\">3</a>] One of the known regulators of endocytosis is the AP2-associated protein kinase 1 (AAK1).",
            "Of 378 AAK1 inhibitors in the knowledge graph, 47 have been approved for medical use and six inhibited AAK1 with high affinity.",
            "These included a number of oncology drugs such as sunitinib and erlotinib, both of which have been shown to inhibit viral infection of cells through",
            "AAK1=AP2-associated protein kinase 1.",
            "GAK=cyclin G-associated kinase.",
            "JAK1/2=janus kinase 1/2.",
            "The inhibition of AAK1.5 these compounds bring serious side-effects, and the data infer high doses to inhibit AAK1 effectively."
        ],
        "Conclusion": [
            "One of the six highaffinity AAK1-binding drugs was the janus kinase inhibitor baricitinib, which binds the cyclin G-associated kinase, another regulator of endo\u00ad cytosis.[<a class=\"ref-link\" id=\"c6\" href=\"#r6\">6</a>] Because the plasma concen\u00ad tration of baricitinib on therapeutic dosing is sufficient to inhibit AAK1, the authors suggest it could be trialled, using an appropriate patient population with 2019-nCoV acute respiratory disease, to reduce both the viral entry and the inflammation in patients, using endpoints such as the MuLBSTA score, an early warning model for predicting mortality in viral pneumonia.[<a class=\"ref-link\" id=\"c7\" href=\"#r7\">7</a>]",
            "JS has previously sat on a number of scientific advisory boards, including BenevolentAI, and has consulted with Lansdowne partners, Vitruvian, and Social Impact Capital; he sits on the Board of Directors for BB Biotech Healthcare Trust and chairs Xerion Healthcare.",
            "BenevolentAI, London, UK (PR, IG, CT, DS, OO, AP); and Department of Surgery and Cancer, Imperial College London, London SW7 2AZ, UK (JS)"
        ]
    },
    "reference_links": [
        {
            "id": "1",
            "alt_id": "Gruber_\"Jan\" # \"Feb\"_a",
            "entry": "1 Gruber CC, Steinkellner G. Wuhan coronavirus 2019-nCoV\u2014what we can find out on a structural bioinformatics level. Jan 23, 2020. https://innophore.com/2019-ncov/ (accessed Feb 3, 2020).",
            "url": "https://innophore.com/2019-ncov/"
        },
        {
            "id": "2",
            "alt_id": "Segler_et+al_2018_a",
            "entry": "2 Segler MHS, Preuss M, Waller P. Planning chemical syntheses with deep neural networks and symbolic AI. Nature 2018; 555: 604\u201310.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Segler%2C%20M.H.S.%20Preuss%2C%20M.%20Waller%2C%20P.%20Planning%20chemical%20syntheses%20with%20deep%20neural%20networks%20and%20symbolic%20AI%202018",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Segler%2C%20M.H.S.%20Preuss%2C%20M.%20Waller%2C%20P.%20Planning%20chemical%20syntheses%20with%20deep%20neural%20networks%20and%20symbolic%20AI%202018",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Segler%2C%20M.H.S.%20Preuss%2C%20M.%20Waller%2C%20P.%20Planning%20chemical%20syntheses%20with%20deep%20neural%20networks%20and%20symbolic%20AI%202018"
        },
        {
            "id": "3",
            "alt_id": "Zhao_et+al_2019_a",
            "entry": "3 Zhao Y, Zhao Z, Wang Y, et al. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. BioRxiv 2020; published online Jan 26. DOI:https://doi.19985.",
            "url": "https://doi.19985"
        },
        {
            "id": "4",
            "alt_id": "Lu_et+al_Jan_a",
            "entry": "4 Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; published online Jan 30. https://doi.org/10.1016/S0140-6736(20)30251-8.",
            "crossref": "https://dx.doi.org/10.1016/S0140-6736(20)30251-8",
            "scite": "https://scite.ai/reports/10.1016/S0140-6736(20)30251-8",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1016/S0140-6736%2820%2930251-8"
        },
        {
            "id": "5",
            "alt_id": "Pu_et+al_2018_a",
            "entry": "5 Pu SY, Xiao F, Schor S, et al. Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment. Antiviral Res 2018, 155: 67\u201375.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Pu%2C%20S.Y.%20Xiao%2C%20F.%20Schor%2C%20S.%20Feasibility%20and%20biological%20rationale%20of%20repurposing%20sunitinib%20and%20erlotinib%20for%20dengue%20treatment%202018",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Pu%2C%20S.Y.%20Xiao%2C%20F.%20Schor%2C%20S.%20Feasibility%20and%20biological%20rationale%20of%20repurposing%20sunitinib%20and%20erlotinib%20for%20dengue%20treatment%202018",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Pu%2C%20S.Y.%20Xiao%2C%20F.%20Schor%2C%20S.%20Feasibility%20and%20biological%20rationale%20of%20repurposing%20sunitinib%20and%20erlotinib%20for%20dengue%20treatment%202018"
        },
        {
            "id": "6",
            "alt_id": "Sorrell_et+al_2016_a",
            "entry": "6 Sorrell F, Szklarz M, Abdul Areez KR, et al. Family-wide structural analysis of human numb-associated protein kinases. Structure 2016; 24: 401\u201311.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Sorrell%2C%20F.%20Szklarz%2C%20M.%20Abdul%20Areez%2C%20K.R.%20Family-wide%20structural%20analysis%20of%20human%20numb-associated%20protein%20kinases%202016",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Sorrell%2C%20F.%20Szklarz%2C%20M.%20Abdul%20Areez%2C%20K.R.%20Family-wide%20structural%20analysis%20of%20human%20numb-associated%20protein%20kinases%202016",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Sorrell%2C%20F.%20Szklarz%2C%20M.%20Abdul%20Areez%2C%20K.R.%20Family-wide%20structural%20analysis%20of%20human%20numb-associated%20protein%20kinases%202016"
        },
        {
            "id": "7",
            "alt_id": "Chen_et+al_Jan_a",
            "entry": "7 Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; published online Jan 29. https://doi.org/10.1016/ S0140-6736(20)30211-7.",
            "url": "https://doi.org/10.1016/S0140-6736(20)30211-7",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Chen%20N%20Zhou%20M%20Dong%20X%20et%20al%20Epidemiological%20and%20clinical%20characteristics%20of%2099%20cases%20of%202019%20novel%20coronavirus%20pneumonia%20in%20Wuhan%20China%20a%20descriptive%20study%20Lancet%202020%20published%20online%20Jan%2029%20httpsdoiorg101016%20S0140673620302117",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Chen%20N%20Zhou%20M%20Dong%20X%20et%20al%20Epidemiological%20and%20clinical%20characteristics%20of%2099%20cases%20of%202019%20novel%20coronavirus%20pneumonia%20in%20Wuhan%20China%20a%20descriptive%20study%20Lancet%202020%20published%20online%20Jan%2029%20httpsdoiorg101016%20S0140673620302117"
        }
    ],
    "facts": [
        "an immediate need for medicines that can help before a vaccine can be produced",
        "with molecular modelling based on the genomes of related virus proteins,1 have suggested a few compounds that are likely to be effective",
        "with molecular modelling based on the genomes of related virus proteins,[1",
        "BenevolentAI's knowledge graph is a large repository of structured medical information",
        "including numerous connections extracted from scientific literature by machine learning.[2",
        "used BenevolentAI to search for approved drugs",
        "which is predicted to reduce the ability of the virus to infect lung cells",
        "These AT2 cells are prone to viral infection.[3",
        "JS has previously sat on a number of scientific advisory boards"
    ],
    "claims": [
        "We identified baricitinib, which is predicted to reduce the ability of the virus to infect lung cells"
    ],
    "findings": [],
    "processes": [],
    "key_statements": [
        "Given the scale and rapid spread of the 2019 novel coronavirus (2019-nCoV) acute respiratory disease, there is an immediate need for medicines that can help before a vaccine can be produced",
        "Results of rapid sequencing of 2019-nCoV, coupled with molecular modelling based on the genomes of related virus proteins,[<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>] have suggested a few compounds that are likely to be effective, including the anti-HIV lopinavir plus ritonavir combination",
        "We identified baricitinib, which is predicted to reduce the ability of the virus to infect lung cells"
    ],
    "top_statements": [
        "Given the scale and rapid spread of the 2019 novel coronavirus (2019-nCoV) acute respiratory disease, there is an immediate need for medicines that can help before a vaccine can be produced",
        "Results of rapid sequencing of 2019-nCoV, coupled with molecular modelling based on the genomes of related virus proteins,[<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>] have suggested a few compounds that are likely to be effective, including the anti-HIV lopinavir plus ritonavir combination",
        "We identified baricitinib, which is predicted to reduce the ability of the virus to infect lung cells"
    ],
    "headline": "Results of rapid sequencing of 2019-nCoV, coupled with molecular modelling based on the genomes of related virus proteins,1 have suggested a few compounds that are likely to be effective, including the anti-HIV lopinavir plus ritonavir combination",
    "contexts": [],
    "abbreviations": {
        "AAK1": "associated protein kinase 1"
    }
}
